The Italian Medicines Agency (AIFA) developed Horizon Scanning (HS) methodology to address programming and sustainability challenges posed by accelerating pharmaceutical innovation and increasing costs. From July 2018 to June 2020, 563 new potential treatments (new medicines and new indications of existing medicines) with an expected impact in 2020–2022 were identified. In this review, we assess and discuss these HS results, including medicine characteristics related to higher prioritization scores, such as clinical areas of major development. After exclusions because of the selection process, 213 (40.6%) new potential treatments were included in the prioritization tool; 25 (11.7%) were shown to be possibly associated with a major impact on healthcare systems (HCSs) according to overall prioritization criteria. Lessons learned from the process led to HS system improvements.

意大利药品管理局 (AIFA) 开发了地平线扫描 (HS) 方法，以解决加速药物创新和增加成本带来的规划和可持续性挑战。从 2018 年 7 月到 2020 年 6 月，确定了 2020-2022 年具有预期影响的 563 种新的潜在疗法（新药和现有药物的新适应症）。在本次审查中，我们评估和讨论了这些 HS 结果，包括与更高优先级评分相关的医学特征，例如主要发展的临床领域。由于选择过程而排除在外后，213 个（40.6%）新的潜在治疗被纳入优先排序工具；根据总体优先级标准，25 (11.7%) 被证明可能与对医疗保健系统 (HCS) 的重大影响有关。